Browse our products

Want to know more?
Reach out to our team to know more about the product or how to purchase
Get more information

Streck CD-Chex CD117® Plus

CD-Chex CD117 Plus is the only commercially available flow cytometry control that includes CD117, CD25 and CD71.

It is a positive procedural control that provides assay values for abnormal and total leukocytes.

CD-Chex CD117 Plus is a ready-to-use control for evaluating surface antigens, including CD117, CD25, and CD71, with monoclonal antibody binding by flow cytometry. It was developed with characteristics similar to abnormal peripheral blood leukocytes often found in a hematolymphoid neoplastic patient sample. The assay provides percent-positive values for CD117, CD25 and CD71 on abnormal and total leukocytes. Abnormal leukocytes are distinguishable from normal leukocytes on the basis of light scatter properties and a low level of CD45 expression.

It is a positive procedural control designed to monitor reagent staining, erythrocyte lysis, sample preparation, and instrument performance. CD-Chex CD117 Plus is compatible with BD Biosciences and Beckman Coulter flow cytometry systems.


  • Only commercially available control assayed for CD117, CD25 and CD71
  • Exhibits characteristics similar to an abnormal peripheral blood patient sample
  • Provides assay values for abnormal and total leukocytes
  • Compatible with BD Biosciences and Beckman Coulter flow cytometry systems
  • 30-day open-vial stability
  • 90-day closed-vial stability


  • Helps toward meeting quality requirements for leukemia and lymphoma immunophenotyping
  • Established assay ranges provide less room for error
  • Reduces the need for labs to hold and validate patient samples for use as a control
  • Access to STATS®, a free interlaboratory quality control program with peer group data comparison and online submission

For more information, visit

Related Products

    Receive our newsletter to get the latest news about our products and services

    * indicates required

    By signing up to our newsletter, you agree to our Data Privacy Policy.